IL-12 enhances protective immunity in mice engendered by immunization with recombinant 14 kDa Schistosoma mansoni fatty acid-binding protein through an IFN-γ and TNF-α dependent pathway

Vaccine

Volumn 22, Issue 3-4, 2004, Pages 503-510

  Fonseca, Cristina T ^a   Brito, Cristiana F A ^b   Alves, José B ^a   Oliveira, Sergio C ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

IL 12; Schistosoma mansoni; Sm14; Vaccine

Indexed keywords

FATTY ACID BINDING PROTEIN; GAMMA INTERFERON; INTERLEUKIN 4; PROTEIN P55; RECOMBINANT INTERLEUKIN 12; RECOMBINANT PROTEIN; SCHISTOSOMA VACCINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; EXPRESSION VECTOR; FEMALE; IMMUNITY; INTERMETHOD COMPARISON; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCHISTOSOMA MANSONI; SUPERNATANT; VACCINATION;

EID: 0344234353     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.07.010     Document Type: Article

References (35)

1. Chitsulo L., Engels D., Montresor A., Savioli L. The global status of schistosomiasis and its control. Acta Trop. 77(1):2000;41-51.
2. Boros D.L. Immunopathology of Schistosoma mansoni infection. Clin. Microbiol. Rev. 2(3):1989;250-269.
3. Harder A. Chemotherapeutic approaches to schistosomes: current knowledge and outlook. Parasitol. Res. 88(5):2002;395-397.
4. Bergquist N.R. Schistosomiasis vaccine development: progress and prospects. Mem. Inst. Oswaldo Cruz. 93(1):1998;95-101.
5. Bergquist N.R. Schistosomiasis vaccine development: approaches and prospects. Mem. Inst. Oswaldo Cruz. 90(2):1995;221-227.
6. Bergquist N.R., Al-Sherbiny M., Barakat R., Olds R. Blueprint for schistosomiasis vaccine development. Acta Trop. 82(2):2002;183-192.
7. Bergquist N.R. Schistosomiasis: from risk assessment to control. Trends Parasitol. 18(7):2002;309-314.
8. Moser D., Tendler M., Griffiths G., Klinkert M. A 14 kDa Schistosoma mansoni polypeptide is homologous to a gene family of fatty acid-binding proteins. J. Biol. Chem. 266(13):1991;8447-8454.
9. Ramos C.R.R., Vilar M.M., do Nascimento A.L., Lee Ho P., Thaumaturgo N., Edelenyi R.et al. r-Sm14-pRSETA efficacy in experimental animals. Mem. Inst. Oswaldo Cruz. 96:2001;131-135.
10. Stek M.F., Minard P., Dean D.A., Hall J.E. Immunization of baboons with Schistosoma mansoni cercariae attenuated by gamma irradiation. Science. 212(4502):1981;1518-1520.
11. Coulson P.S. The radiation-attenuated vaccine against schistosomes in animal models: paradigm for human vaccine? Adv. Parasitol. 39:1997;271-336.
12. + T cells in immunity to Schistosoma mansoni induced by 20 krad-irradiated and Ro 11-3128-terminated infections. Immunology. 67(4):1989;466-472.
13. Smythies L.E., Coulson P.S., Wilson R.A. Monoclonal antibody to IFN-gamma modifies pulmonary inflammatory responses and abrogates immunity to Schistosoma mansoni in mice vaccinated with attenuated cercariae. J. Immunol. 149(11):1992;3654-3658.
14. Wilson R.A., Coulson P.S., Betis C., Dowking M.A., Smythies L.E. Impaired immunity and altered pulmonary response in mice with a disrupted interferon-γ receptor gene exposed to the irradiated Schistosoma mansoni vaccine. Immunology. 87(2):1996;275-282.
15. Jankovic D., Wynn T.A., Kullberg M.C., Caspar R., James S., Cheever A.W.et al. Optimal vaccination against Schistosoma mansoni requires the induction of both B cell and IFN-γ dependent effector mechanisms. J. Immunol. 162(1):1999;345-351.
16. Abbas A.K., Murphy K.M., Sher A. Functional diversity of helper T lymphocytes. Nature. 383(6603):1996;787-793.
17. Katae M., Miyahira Y., Takeda K., Matsuda H., Yagita H., Okumura K.et al. Coadministration of an interleukin-12 gene and a Trypanosoma cruzi gene improves vaccine efficacy. Infect. Immun. 70(9):2002;4833-4840.
18. Letscher-Bru V., Villard O., Risse B., Zauke M., Klein J.P., Kien T.T. Protective effect of vaccination with a combination of recombinant surface antigen 1 and interleukin-12 against toxoplasmosis in mice. Infect. Immun. 66(9):1998;4503-4506.
19. Afonso L.C., Scharton T.M., Vieira L.Q., Wysocko M., Trinchieri G., Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science. 263(5144):1994;235-237.
20. Wynn T.A., Jankovic D., Hieny S., Cheever A.W., Sher A. IL-12 enhances vaccine-induced immunity to Schistosoma mansoni in mice and decreases T helper 2 cytokine expression, IgE production, and tissue eosinofilia. J. Immunol. 154(9):1995;4701-4709.
21. Argiro L., Henri S., Dessein H., Dessein A.J., Bourgois A. Induction of a protective immunity against Schistosoma mansoni with ovalbumin-coupled Sm37-5 coadsorbed with granulocyte-macrophage colony stimulating factor (GM-CSF) or IL-12 on alum. Vaccine. 17(1):1999;13-18.
22. Eberl M., Beck E., Coulson P.S., Okamura H., Wilson R.A., Mountford A.P. IL-18 potentiates the adjuvant properties of IL-12 in the induction of a strong Th1 type immune response against a recombinant antigen. Vaccine. 18(19):2000;2002-2008.
23. Brito C.F.A., Fonseca C.T., Goes A.M., Simpson A.J.G., Oliveira S.C. Human IgG1 and IgG3 recognition of Schistosoma mansoni 14 kDa fatty acid-binding protein. Parasite Immunol. 22(1):2000;41-48.
24. Smythies S.R., Terry R.J. The infection of laboratory hosts with cercariae of Schistosoma mansoni and recovery of adult worms. Parasitology. 55(4):1965;695-700.
25. Hirata M., Takushima M., Kage M., Fukuma T. Comparative analysis of hepatic, pulmonary, and intestinal granuloma formation around freshly laid Schistosoma japonicum eggs in mice. Parasitol. Res. 79(4):1993;316-321.
26. Wynn T.A., Reynolds A., James S., Cheever A.W., Caspar P., Hieny S.et al. IL-12 enhances vaccine induced immunity to Schistosoma mansoni by augmenting both humoral and cell mediated immune response against the parasite. J. Immunol. 157(9):1996;4068-4078.
27. Wynn T.A., Hoffmann K.F. Defining a schistosomiasis vaccination strategy - is it really Th1 versus Th2? Parasitol. Today. 16(11):2000;497-501.
28. Tendler M., Brito C.A., Vilar M.M., Freire N.S., Diogo C.M., Almeida M.A.et al. A Schistosoma mansoni fatty acid-binding protein, Sm14, is a potential basis of a dual-purpose anti-helminthes vaccine. Proc. Natl. Acad. Sci. U.S.A. 93(1):1996;269-273.
29. Grun J.L., Maurer P.H. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin-1 in proliferative response. Cell. Immunol. 121(1):1989;134-145.
30. Finkelman F.D., Holmes J., Katona I.M., Urban J.F. Jr., Beckmann M.P., Park L.S.et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol. 8:1990;303-333.
31. + T cells: IL-4 is essential for induction of antigen specific antibody response by Th2 but not Th1 clones. Eur. J. Immunol. 20(10):1990;2219-2227.
32. + T cells of schistosomiasis naturally resistant individuals living in an endemic area produce interferon-gamma and tumour necrosis factor-alpha in response to the recombinant 14 kDa Schistosoma mansoni fatty acid-binding protein. Scand. J. Immunol. 51(6):2000;595-601.
33. Street M., Coulson P.S., Sadler C., Warnock L.J., McLaughlin D., Bluethmann H.et al. TNF is essential for the cell-mediated protective immunity induced by the radiation-attenuated schistosome vaccine. J. Immunol. 163(8):1999;4489-4494.
34. Wynn T.A., Cheever A.W. Cytokine regulation of granuloma formation in schistosomiasis. Curr. Opin. Immunol. 7(4):1995;505-511.
35. Wynn T.A., Cheever A.W., Jankovic D., Poindexter R.W., Caspar P., Lewis F.A.et al. An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature. 376(6541):1995;594-596.